|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Fresenius Medical Care AG & Co. KGaA, a provider of products and services for individuals undergoing dialysis because of chronic kidney failure. |
|---|---|
| Transferring Party | The phosphate binder business from Nabi Biopharmaceuticals Inc.( NABI), a developer of therapies for hepatitis and transplant, kidney disease, Gram-positive bacterial infections and nicotine addiction. |
| Sector | Biopharmaceuticals |
| Date | November 15, 2006 |
| Analysis Expands Fresenius' clinical therapy offerings, to better manage bone mineralization during dialysis treatment. Deal value -- $65m plus $20m in earnouts. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |